A research-use-only (RUO) peptide reagent is not active pharmaceutical ingredient for 503A compounding. Those are two different objects: a laboratory chemical sold with a research intended use, and a bulk drug substance that a licensed pharmacy may use, when compounding is allowed at all, under the Federal Food, Drug, and Cosmetic Act.
That distinction is not a loophole and it is not a workaround. It is the opposite. State boards and FDA have said, in public documents, that products labeled research use only are not for compounding. This article is orientation for people who keep seeing those two worlds mashed together in forums. It is not legal advice, not compounding advice, and not a claim about any specific pharmacy.
Section 503A of the FD&C Act (21 U.S.C. § 353a) is about pharmacy compounding for identified patients, with conditions that keep a compounded preparation from being treated as an unapproved new drug in the same way a manufacturer’s product would be. It is a pharmacy path. It assumes a licensed compounder, a prescription or order, and bulk substances that meet the statute’s source rules.
A research catalog is not that path. The intended use is laboratory research. The vial is not offered as a drug. A certificate of analysis is a lot report. It is not an NDA, and it is not a ticket into 503A. Mixing the paperwork is how people talk themselves into thinking a purity percentage is a license.
Section 503B is a different compounding track (outsourcing facilities). It has its own lists and CGMP conditions. Naming 503B does not convert an RUO reagent into 503B bulk either. The label still states the intended use.
What Ohio wrote down (17 July 2025)
The Ohio Board of Pharmacy’s document Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, dated 17 July 2025, answers a sourcing question in plain language. Under federal requirements, pharmacies, clinics, and outsourcing facilities must ensure that API is a pharmaceutical-grade product, accompanied by a valid certificate of analysis, and sourced from an establishment registered with FDA under section 510 of the FD&C Act.
Then the Board states the line that belongs on this page: “Research use only” products, or products produced by establishments which are not registered with the FDA, may not be used for compounding in any circumstance.
The same FAQ notes that drugs labeled “research use only” are not approved for use as investigational new drugs. INDs used in approved clinical trials have their own required caution statement under 21 CFR 312.6. An RUO sticker is not that statement.
Ohio is one state board speaking about GLP-1 compounding questions it was actually receiving. It is not a national regulation by itself. It is a citable example of how a regulator separates reagent catalogs from compounding API. Other boards have said the same kind of thing. Oregon’s semaglutide position statement, for example, also states that RUO products, or products from establishments not registered with FDA, may not be used for compounding.
Shortage windows do not rewrite the reagent
During FDA shortage periods, compounding of certain GLP-1 products was treated differently than it is when the approved products are commercially available. Ohio’s July 2025 chart records that, for tirzepatide and semaglutide, compounding of essential copies was no longer permitted after the FDA end dates listed in that document (pharmacy/prescriber and outsourcing-facility dates differ). Those dates are about copies of approved drugs, not about converting research vials into API.
Even when compounding of a GLP-1 was discussed as permissible under shortage or “significant difference” rules, Ohio still required pharmaceutical-grade API from an FDA-registered establishment. RUO stayed out. A shortage list is not a catalog exemption.
The Board also states that retatrutide and cagrilintide cannot be used in compounding under federal and state law as described in that document: they are not a component of an FDA-approved drug, are not on the relevant bulk list, and do not have USP/NF monographs. That is a compounding-law statement about those substances. It is not a research-use statement, and it is not a shopping guide.
Worked example: which document answers which question
Question
Research reagent COA
503A compounding file
What is the intended use?
Laboratory research, as labeled
A compounded drug for an identified patient, when compounding is allowed
Does HPLC purity authorize use in people?
No
No. Compounding has its own legal conditions.
Is “research use only” on the label compatible with compounding?
The label states research use
Ohio: RUO may not be used for compounding in any circumstance
Who is the buyer in the paperwork?
A laboratory purchasing a chemical
A licensed pharmacy or prescriber operating under compounding law
How this sits next to salt-versus-base
Even on the compounding side, the approved incretin products are not “whatever semaglutide-like powder is in the drawer.” FDA has stated that salt forms of semaglutide are different active ingredients than the approved drugs. Ohio states that Ozempic, Wegovy, and Rybelsus contain semaglutide base, and that Mounjaro and Zepbound contain tirzepatide base. That is a separate note: incretin salt forms are not the approved-drug base.
Stack the two facts and the forum shortcut dies twice. An RUO reagent is the wrong object. A salt form, even in a compounding conversation, is not the component of the approved drug. Neither fact is an invitation to compound. Both are identity and labeling facts.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 353a (pharmacy compounding).
Ohio Board of Pharmacy. Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio. Date issued 17 July 2025. https://www.pharmacy.ohio.gov/documents/pubs/special/compounding/compounding%20of%20glp-1%20drug%20products%20in%20ohio.pdf
Oregon Board of Pharmacy. Semaglutide position statement (v. 2/2025): RUO products may not be used for compounding.
U.S. Food and Drug Administration. Human drug compounding. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
21 CFR 312.6 (investigational new drug labeling).
For laboratory research only. Not for human or veterinary use. This article is not legal advice and not medical advice.
A Research Reagent Is Not 503A API
A research-use-only (RUO) peptide reagent is not active pharmaceutical ingredient for 503A compounding. Those are two different objects: a laboratory chemical sold with a research intended use, and a bulk drug substance that a licensed pharmacy may use, when compounding is allowed at all, under the Federal Food, Drug, and Cosmetic Act.
That distinction is not a loophole and it is not a workaround. It is the opposite. State boards and FDA have said, in public documents, that products labeled research use only are not for compounding. This article is orientation for people who keep seeing those two worlds mashed together in forums. It is not legal advice, not compounding advice, and not a claim about any specific pharmacy.
For what the RUO label actually means on a catalog page, see what “research use only” means for peptides.
Two statutes, two jobs
Section 503A of the FD&C Act (21 U.S.C. § 353a) is about pharmacy compounding for identified patients, with conditions that keep a compounded preparation from being treated as an unapproved new drug in the same way a manufacturer’s product would be. It is a pharmacy path. It assumes a licensed compounder, a prescription or order, and bulk substances that meet the statute’s source rules.
A research catalog is not that path. The intended use is laboratory research. The vial is not offered as a drug. A certificate of analysis is a lot report. It is not an NDA, and it is not a ticket into 503A. Mixing the paperwork is how people talk themselves into thinking a purity percentage is a license.
Section 503B is a different compounding track (outsourcing facilities). It has its own lists and CGMP conditions. Naming 503B does not convert an RUO reagent into 503B bulk either. The label still states the intended use.
What Ohio wrote down (17 July 2025)
The Ohio Board of Pharmacy’s document Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, dated 17 July 2025, answers a sourcing question in plain language. Under federal requirements, pharmacies, clinics, and outsourcing facilities must ensure that API is a pharmaceutical-grade product, accompanied by a valid certificate of analysis, and sourced from an establishment registered with FDA under section 510 of the FD&C Act.
Then the Board states the line that belongs on this page: “Research use only” products, or products produced by establishments which are not registered with the FDA, may not be used for compounding in any circumstance.
The same FAQ notes that drugs labeled “research use only” are not approved for use as investigational new drugs. INDs used in approved clinical trials have their own required caution statement under 21 CFR 312.6. An RUO sticker is not that statement.
Ohio is one state board speaking about GLP-1 compounding questions it was actually receiving. It is not a national regulation by itself. It is a citable example of how a regulator separates reagent catalogs from compounding API. Other boards have said the same kind of thing. Oregon’s semaglutide position statement, for example, also states that RUO products, or products from establishments not registered with FDA, may not be used for compounding.
Shortage windows do not rewrite the reagent
During FDA shortage periods, compounding of certain GLP-1 products was treated differently than it is when the approved products are commercially available. Ohio’s July 2025 chart records that, for tirzepatide and semaglutide, compounding of essential copies was no longer permitted after the FDA end dates listed in that document (pharmacy/prescriber and outsourcing-facility dates differ). Those dates are about copies of approved drugs, not about converting research vials into API.
Even when compounding of a GLP-1 was discussed as permissible under shortage or “significant difference” rules, Ohio still required pharmaceutical-grade API from an FDA-registered establishment. RUO stayed out. A shortage list is not a catalog exemption.
The Board also states that retatrutide and cagrilintide cannot be used in compounding under federal and state law as described in that document: they are not a component of an FDA-approved drug, are not on the relevant bulk list, and do not have USP/NF monographs. That is a compounding-law statement about those substances. It is not a research-use statement, and it is not a shopping guide.
Worked example: which document answers which question
How this sits next to salt-versus-base
Even on the compounding side, the approved incretin products are not “whatever semaglutide-like powder is in the drawer.” FDA has stated that salt forms of semaglutide are different active ingredients than the approved drugs. Ohio states that Ozempic, Wegovy, and Rybelsus contain semaglutide base, and that Mounjaro and Zepbound contain tirzepatide base. That is a separate note: incretin salt forms are not the approved-drug base.
Stack the two facts and the forum shortcut dies twice. An RUO reagent is the wrong object. A salt form, even in a compounding conversation, is not the component of the approved drug. Neither fact is an invitation to compound. Both are identity and labeling facts.
Related reading: What research use only means for peptides · How to read a peptide COA · Incretin salt forms are not the approved-drug base
References
For laboratory research only. Not for human or veterinary use. This article is not legal advice and not medical advice.
Last reviewed: 2026-10-14